Patients could be denied treatments, says BIA
Samsung to take on patent thicket surrounding Humira.
Industry giants such as AstraZeneca and Novartis are on board.
This week’s news
Multi-centre trial of Ortho-ATI technology planned for early 2017.
Afinitor finally recommended after rejection in 2011.
Settlement relates to investigation into Dermagraft sales.
Approval by May could put Keytruda in pole position
Project aims to improve population health management.
Sales of Humira could peak above $18 billion – CEO
Allergan to co-develop Parkinson’s drug with Lysosomal Therapeutics
PM under fire over A&E waiting times.
California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Company sacks a further 155 employees in “re-engineering” efforts.
Biotech specialises in autoimmune disorder drugs.